Celecoxib versus ibuprofen in the prevention of heterotopic ossification following total hip replacement: a prospective randomised trial
|
|
- Arabella Adams
- 5 years ago
- Views:
Transcription
1 Article Celecoxib versus ibuprofen in the prevention of heterotopic ossification following total hip replacement: a prospective randomised trial SAUDAN, Marc, et al. Abstract We examined whether a selective cyclooxygenase-2 (COX-2) inhibitor (celecoxib) was as effective as a non-selective inhibitor (ibuprofen) for the prevention of heterotopic ossification following total hip replacement. A total of 250 patients were randomised to receive celecoxib (200 mg b/d) or ibuprofen (400 mg t.d.s) for ten days after surgery. Anteroposterior radiographs of the pelvis were examined for heterotopic ossification three months after surgery. Of the 250 patients, 240 were available for assessment. Heterotopic ossification was more common in the ibuprofen group (none 40.7% (50), Brooker class I 46.3% (57), classes II and III 13.0% (16)) than in the celecoxib group (none 59.0% (69), Brooker class I 35.9% (42), classes II and III 5.1% (6), p=0.002). Celecoxib was more effective than ibuprofen in preventing heterotopic bone formation after total hip replacement. Reference SAUDAN, Marc, et al. Celecoxib versus ibuprofen in the prevention of heterotopic ossification following total hip replacement: a prospective randomised trial. Journal of Bone and Joint Surgery. British Volume, 2007, vol. 89, no. 2, p DOI : / X.89B PMID : Available at: Disclaimer: layout of this document may differ from the published version.
2 Hip Celecoxib versus ibuprofen in the prevention of heterotopic ossification following total hip replacement A PROSPECTIVE RANDOMISED TRIAL M. Saudan, P. Saudan, T. Perneger, N. Riand, A. Keller, P. Hoffmeyer From the University Hospitals of Geneva, Geneva, Switzerland We examined whether a selective cyclo-oxygenase-2 (COX-2) inhibitor (celecoxib) was as effective as a non-selective inhibitor (ibuprofen) for the prevention of heterotopic ossification following total hip replacement. A total of 250 patients were randomised to receive celecoxib (200 mg b/d) or ibuprofen (400 mg t.d.s) for ten days after surgery. Anteroposterior radiographs of the pelvis were examined for heterotopic ossification three months after surgery. Of the 250 patients, 240 were available for assessment. Heterotopic ossification was more common in the ibuprofen group (none 40.7% (50), Brooker class I 46.3% (57), classes II and III 13.0% (16)) than in the celecoxib group (none 59.0% (69), Brooker class I 35.9% (42), classes II and III 5.1% (6), p = 0.002). Celecoxib was more effective than ibuprofen in preventing heterotopic bone formation after total hip replacement. M. Saudan, MD, Orthopaedic Surgeon N. Riand, MD, Orthopaedic Surgeon P. Hoffmeyer, MD, Professor Division of Orthopaedic Surgery P. Saudan, MD, Physician Division of Nephrology T. Perneger, PhD, Professor Quality of Care Unit A. Keller, MD, Physician Department of Radiology University Hospitals of Geneva, Rue Micheli-du-Crest 24, CH Genèva 14, Switzerland. Correspondence should be sent to Dr M. Saudan; marc.saudan@hcuge.ch 2007 British Editorial Society of Bone and Joint Surgery doi: / x.89b $2.00 J Bone Joint Surg [Br] 2007;89-B: Received 7 February 2006; Accepted after revision 20 September 2006 Heterotopic bone formation is a common complication of total hip replacement (THR). 1-4 In a study of patients who underwent THR, more than half had radiological evidence of heterotopic ossification (HO), and of these 15% were symptomatic. 1 Severe HO may cause protracted post-operative pain and impaired function and it may require excision. A recent meta-analysis encompassing 30 studies concluded that HO impairs movement of the hip. 5 Another report noted that whereas 90% of patients without HO were satisfied with their operation, only approximately 30% with severe HO were. 6 Prevention of HO is therefore important for patients undergoing elective THR. Post-operative radiotherapy significantly reduces the incidence of HO, 7 but is not widely available. Prevention with low-dose aspirin has given conflicting results, 8,9 but several small trials have suggested that non-steroidal anti-inflammatory drugs (NSAIDs) are effective. 2,3 This has led to their widespread use both before operation and in the immediate post-operative period for the prevention of HO. Their inhibitory effect on the formation of HO was described in 1974 using diclofenac. 10,11 Other NSAIDs, such as ibuprofen, have been found to be as effective and there is a trend towards reducing the treatment time and dosage to diminish the side-effects. 11,12 Ibuprofen has been shown to be effective in a dose of 400 mg three times a day for eight days, 13,14 and this has become the regimen for prophylaxis in our hospital. The exact mechanism of action of NSAIDs on bone formation is unclear. These compounds are believed to inhibit the cyclo-oxygenase (COX) enzyme and impair the transformation of arachidonic acid into prostaglandins and thromboxanes. There are two isoforms of COX, COX-1 and COX-2, and their localisation and expression are different. COX-1 localises in most tissues and participates in the regulation of normal cellular processes, but COX-2 is expressed more selectively during inflammatory states, and localises in the brain, bone and kidney. 15 Most NSAIDs are nonselective inhibitors of both COX-1 and COX-2. Because COX-1 is involved in gastric cytoprotection, non-selective inhibitors seem to induce more gastroduodenal toxicity. 16 An argument can be made for the use of selective COX-2 inhibitors in elderly patients undergoing THR to avoid this. However, because of the selective expression of COX-2 in bone tissue, it is unclear whether selective inhibitors would be equally effective at preventing heterotopic bone formation. The aim of this study was to investigate whether celecoxib, a selective COX-2 inhibitor, would be as effective as ibuprofen, a non-selective COX inhibitor, in the prevention of HO in patients undergoing THR. Patients and Methods A prospective randomised trial of celecoxib versus ibuprofen in the prophylaxis of HO VOL. 89-B, No. 2, FEBRUARY
3 156 M. SAUDAN, P. SAUDAN, T. PERNEGER, N. RIAND, A. KELLER, P. HOFFMEYER 310 patients screened 250 patients included 123 patients randomised to the celecoxib group 127 patients randomised to the ibuprofen group 2 died 4 lost to follow-up 3 died 1 lost to follow-up 117 analysed 123 analysed Treatment interrupted 1 GI disorder 6 renal impairments 1 allergy 6 other Treatment interrupted 3 GI disorder 4 renal impairments 5 other 103 patients with treatment completed 111 patients with treatment completed Fig. 1 Trial profile (GI, gastrointestinal). following THR was set up. The patients and healthcare teams were not blinded to treatment allocation, but the physicians who assessed the outcome were. The Ethics Committee of the Department of Surgery approved the study and all the patients provided written consent. Between January 2001 and August 2002, all patients with severe osteoarthritis of the hip who were scheduled for elective THR were evaluated. Exclusion criteria included patients with moderate to severe renal impairment (serum creatinine > 2 mg/dl), a history of gastrointestinal ulcers, immediate-type hypersensitivity to NSAIDs or COX-2 inhibitors, and refusal to participate in the study. Patients were randomised at the anaesthetic evaluation three months prior to surgery by opening consecutive sealed opaque envelopes which contained a computergenerated code. The randomisation was in blocks of six, eight or ten. Patients were allocated to receive either ibuprofen 400 mg three times daily or celecoxib 200 mg twice daily. Until the date of the operation, specific medication was prescribed as needed for pain control. In the celecoxib group, 80 patients received it and four were treated with an NSAID for pre-operative pain control. In the ibuprofen group, nine patients received celecoxib and 58 an NSAID pre-operatively. Ibuprofen or celecoxib were started or resumed on the first post-operative day and continued for a total of ten days. All the patients underwent THR via a direct lateral approach, with an uncemented acetabular component and a cemented femoral stem. Prophylaxis for deep venous thrombosis was implemented with low molec- THE JOURNAL OF BONE AND JOINT SURGERY
4 CELECOXIB VERSUS IBUPROFEN IN THE PREVENTION OF HETEROTOPIC OSSIFICATION FOLLOWING TOTAL HIP REPLACEMENT 157 Table I. Baseline and treatment characteristics of the study participants Celecoxib Ibuprofen Number of patients Mean age (range) 69 (38 to 95) 70 (34 to 91) Male gender (%) 58 (47) 58 (46) Cause of joint damage (%) Primary osteoarthritis 108 (88) 118 (93) Secondary osteoarthritis 9 (7) 4 (3) Necrosis 5 (4) 2 (1.5) Dysplasia 0 (0) 1 (1) Other 1 (1) 2 (1.5) Treatment with NSAID * prior to the operation (%) 4 (3) 58 (46) Treatment with selective COX-2 inhibitor prior to the operation (%) 80 (65) 9 (7) No treatment with NSAID or selective COX-2 inhibitor prior to the operation (%) 39 (32) 60 (47) Serum creatinine in mg/dl, mean (range) 0.9 (0.7 to 1.3) 0.9 (0.6 to 1.2) Operating time in minutes, mean (range) 127 (70 to 260) 130 (70 to 255) Hip prosthesis (%) Hybrid 117 (95) 121 (95) Cemented 6 (5) 6 (5) * NSAID, non-steroidal anti-inflammatory drug COX-2, cyclo-oxygenase 2 ular weight heparin (Fraxiparin) for five days after operation, and then oral anticoagulation (acenocoumarol) was given for the following six weeks. A total of 310 patients scheduled for THR were evaluated, and of these, 250 agreed to participate in the trial. At the three-month follow-up after operation, 240 were available for radiological assessment, 123 in the ibuprofen group, and 117 in the celecoxib group (Fig. 1). Patients in the two groups were similar in age, gender, aetiology of hip disease and renal impairment (Table I). During the initial ten post-operative days, treatment was discontinued in 14 patients taking celecoxib and in 12 taking ibuprofen. An increase in plasma creatinine > 0.5 mg/dl necessitating discontinuation of the drug occurred in ten patients, four receiving ibuprofen and six on celecoxib. After the medication was stopped the serum creatinine returned to baseline levels in all patients except in one receiving ibuprofen, who died from multiple organ dysfunction. Electrolyte disorders did not occur in any patients. Gastrointestinal complications were limited to one patient in the celecoxib group, and three in the ibuprofen group. As the patients were randomised prior to the operation, most of those who needed painkillers could receive the medication which they were allotted within the pre-operative period (Table I). Outcome measures. The primary outcome variable was the presence of HO on an anterior-posterior radiograph of the pelvis three months after operation. Radiographs were read independently by a radiologist (AK) and an orthopaedic surgeon (NR), who were unaware of the medication the patient had received. The presence of HO was assessed according to the Brooker classification. 3 Brooker class I lesions correspond to islands of bone within the soft tissues around the hip, class II are bone spurs from the pelvis or proximal aspect of the femur, leaving at least 1 cm between the opposing bone surfaces, class III are bone spurs from the pelvis or proximal femur which reduce the space between opposing bone surfaces to less than 1 cm and class IV lesions correspond to apparent ankylosis of the hip. The reliability of scoring by the observers was examined before the trial by repeated reading of 30 pelvic radiographs containing HO, read twice at one-month intervals. Inter-observer analyis revealed a κ value of In addition, the following adverse events in the post-operative period until hospital discharge were documented: 1) renal impairment, defined as an increase in plasma creatinine of 0.5 mg/dl from the baseline value; 2) electrolyte disorders, defined as serum sodium (Na) < 125 mmol/l or serum potassium (K) > 5 mmol/l; 3) gastrointestinal disturbances, including any symptoms that could be related to oesophageal, gastric or duodenal ulceration. Functional outcomes were not assessed because the observers in charge of clinical follow-up were not blinded to the treatments. Statistical methods. For the equivalence study, we considered that a difference of SD 0.25 between means (continuous scoring) would be compatible with equivalence of the two groups. To achieve a power of 70%, (one-sided test, α = 0.05) 150 patients were required in each group. The characteristics of the two patient groups were compared at baseline. Outcomes were compared on an intentionto-treat basis. A chi-squared test was used to assess a linear trend for the ordinal ossification score. Because of the small numbers of observations, Brooker classes II and III were pooled in the final analysis. Statistical modelling was carried out using multinomial logistic regression, where no calcification was taken as the reference level. In the unadjusted model, treatment as randomised was the only predictor. However, in the adjusted model, patient gender, age, duration of operation (in minutes), and whether the patient was treated with anti-inflammatory drugs before the operation were taken as additional predictions. All statistical tests were two-tailed. A p-value of < 0.05 was considered significant. VOL. 89-B, No. 2, FEBRUARY 2007
5 158 M. SAUDAN, P. SAUDAN, T. PERNEGER, N. RIAND, A. KELLER, P. HOFFMEYER Number of patients (%) None Mild Moderate-severe Severity of heterotopic ossification Fig. 2 Distribution of heterotopic ossification following total hip replacement in patients treated with ibuprofen (dark-grey bars) and celecoxib (lightgrey bars) (Mild = Brooker class I, moderate severe = Brooker class II and III). Results More HO was identified in patients treated with ibuprofen (none, 50 (40.7%), Brooker class I, 57 (46.3%), classes II and III, 16 (13.0%)) than in patients treated with celecoxib (none, 69 (59.0%), Brooker class I, 42 (35.9%), classes II and III, 6 (5.1%), p-value for linear trend 0.002) (Fig. 2). In adjusted multinomial logistic regression analysis, ibuprofen was associated with an increased risk of Brooker class I HO (odds ratio (OR) 1.9, 95% confidence interval (CI) 1.1 to 3.2) and of classes II and III (OR 3.7, 95% CI 1.3 to 10.1), compared with treatment with celecoxib. Adjustment for age, gender, duration of surgery, and anti-inflammatory treatment before surgery had no effect on these results, as ibuprofen was still associated with an increased risk of Brooker class I (OR 2.0, 95% CI 1.1 to 3.5) and classes II and III (OR 4.0, 95% CI 1.4 to 11.1). Among the potential confounding variables, only male gender was associated with an increased risk of HO (adjusted OR of any HO 2.1, 95% CI 1.2 to 3.6). Discussion In this study a ten-day prophylaxis with celecoxib in the post-operative period was found to reduce the risk of Brooker class I HO by 50% and the risk of classes II and III HO by 75% compared with ibuprofen, based respectively on the difference in adjusted odds ratio for the appearance of Brooker classes I and classes II and III combined. The incidence of gastrointestinal and renal problems did not differ between the two groups, but our trial was not powered to detect such differences. Prescription of coxibs in the post-operative period seems rather safe. Their lack of interaction with platelet aggregation 17 explains that no increase in blood loss was demonstrated in patients undergoing total knee replacement. 18 Coxibs such as rofecoxib have been implicated in an increased long-term cardiovascular risk compared with classic NSAIDs. 19 An increased incidence of cardiovascular events associated with the use of rofecoxib or celecoxib became apparent only after 12 to 18 months of continuous treatment. 20,21 However, even with the short-term use of these drugs in patients prone to cardiovascular disorders, caution should be exercised. 22 What could be the likely explanation for the difference in efficacy between celecoxib and ibuprofen in preventing HO? Animal studies suggest that COX-2 receptors are involved in the formation of endochondral bone following a fracture. 23 The inflammation induced by a fracture produces prostaglandins through COX-2 activation, which is necessary for healing. In mice, activation of COX-2 regulates mesenchymal cell differentiation and osteoblastogenesis; fracture healing was delayed in a knockout mouse model selectively deleting the COX-2 gene. 24 It has also been shown that inhibition of COX-2 with rofecoxib suppresses bone formation in New Zealand White rabbits. 25 Therefore, it is likely that COX-2 selective inhibitors may inhibit not only fracture healing but also heterotopic bone formation. There is very little information available on the use of coxibs in patients at risk for the development of HO. Although a recent study suggested that meloxicam was no better than indometacin in preventing HO, meloxicam is not a pure COX-2 inhibitor. 26 Indometacin administered post-operatively at a dose of 25 mg three times daily for ten days in patients with an uncemented THR significantly deterred the formation of HO while having no deleterious effect on fixation of the implant at 24 post-operative months. 27 However, inhibition of bone formation by coxibs could impair the long-term fixation of an uncemented THR to bone. We acknowledge that there are some limitations in our study. We were unable to blind the patients and the surgeons to their specific treatment group. Therefore, our assessment of HO was only radiological. However, the classification of HO was made by physicians who were not involved in patient care and were blinded to the treatment. Radiological assessment at three months may be too preliminary, as some HO may mature up to 12 months postoperatively. 28 However, 96% of HO appears on radiographs within six weeks of surgery. 28 The sample size did not permit a determination of whether celecoxib was superior to ibuprofen in terms of side effects. Patients with chronic renal failure or those with a past history of gastrointestinal ulcers were excluded from this study, and our conclusions need to be validated in these high-risk populations. Our findings suggest that celecoxib is more effective than ibuprofen in preventing HO following THR. These results, as well as previous reports demonstrating reduced gastro- THE JOURNAL OF BONE AND JOINT SURGERY
6 CELECOXIB VERSUS IBUPROFEN IN THE PREVENTION OF HETEROTOPIC OSSIFICATION FOLLOWING TOTAL HIP REPLACEMENT 159 intestinal side effects, suggest that following THR, a short period of prophylaxis with selective COX-2 inhibitors may be the preferred treatment for the prevention of HO. Longer follow-up is necessary to ascertain whether celecoxib impairs the long-term fixation of an uncemented THR to bone. We thank Dr Richard Stern for his critical review of the manuscript. No benefits in any form have been received or will be received from a commercial party related directly or indirectly to the subject of this article. References 1. Ahrengart L. Periarticular heterotopic ossification after total hip arthroplasty: risk factors and consequences. Clin Orthop 1991;263: Barthel T, Baumann B, Noth U, Eulert J. Prophylaxis of heterotopic ossification after total hip arthroplasty: a prospective randomized study comparing indomethacin and meloxicam. Acta Orthop Scand 2002;73: Brooker AF, Bowerman JW, Robinson RA, Riley LH Jr. Ectopic ossification following total hip replacement: incidence and a method of classification. J Bone Joint Surg [Am] 1973;55-A: Cella JP, Salvati EA, Sculco TP. Indomethacin for the prevention of heterotopic ossification following total hip arthroplasty: effectiveness, contraindications, and adverse effects. J Arthroplasty 1988;3: Neal B. Effects of heterotopic bone formation on outcome after hip arthroplasty. ANZ J Surg 2003;73: Eggli S, Rodriguez J, Ganz R. Heterotopic ossification in total hip arthroplasty: the significance for clinical outcome. Acta Orthop Belg 2000;66: Knelles D, Barthel T, Karrer A, et al. Prevention of heterotopic ossification after total hip replacement: a prospective, randomised study using acetylsalicylic acid, indomethacin and fractional or single-dose irradiation. J Bone Joint Surg [Br] 1997;79-B: Pagnani MJ, Pellicci PM, Salvati EA. Effect of aspirin on heterotopic ossification after total hip arthroplasty in men who have osteoarthrosis. J Bone Joint Surg [Am] 1991;73-A: Neal BC, Rodgers A, Gray H, et al. No effect of low-dose aspirin for the prevention of heterotopic bone formation after total hip replacement: a randomized trial of 2,649 patients. Acta Orthop Scand 2000;71: Dahl H. Kliniske observajoner. In: Symposium about hip arthrosis Ritter MA, Sieber JM. Prophylactic indomethacin for the prevention of heterotopic bone formation following total hip arthroplasty. Clin Orthop 1985;196: Schmidt SA, Kjaersgaard-Andersen P, Pedersen NW, et al. The use of indomethacin to prevent the formation of heterotopic bone after total hip replacement: a randomized, double-blind clinical trial. J Bone Joint Surg [Am] 1988;70- A: Elmstedt E, Lindholm TS, Nilsson OS, Tornkvist H. Effect of ibuprofen on heterotopic ossification after hip replacement. Acta Orthop Scand 1985;56: Persson PE, Sodemann B, Nilsson OS. Preventive effects of ibuprofen on periarticular heterotopic ossification after total hip arthroplasty: a randomised doubleblind prospective study of treatment time. Acta Orthop Scand 1998;69: Dubois RN, Abramson SB, Crofford L, et al. Cyclooxygenase in biology and disease. Faseb J 1998;12: Smalley WE, Griffin MR. The risks and costs of upper gastrointestinal disease attributable to NSAIDs. Gastroenterol Clin North Am 1996;25: Greenberg HE, Gottesdiener K, Huntington M, et al. A new cyclooxygenase-2 inhibitor, rofecoxib (VIOXX), did not alter the antiplatelet effects of low-dose aspirin in healthy volunteers. J Clin Pharmacol 2000;40: Reuben SS, Fingeroth R, Krushell R, et al. Evaluation of safety and efficacy of the perioperative administration of rofecoxib for total knee arthroplasty. J Arthroplasty 2002;17: Juni P, Nartey L, Reichenbach S, Sterchi R, et al. Risk of cardiovascular events and rofecoxib: cumulative meta-analaysis. Lancet 2004;364: Bresalier RS, Sandler RS, Quan H, et al. Cardiovascular events associated with rofecoxib in a colorectal adenoma chemoprevention trial. N Engl J Med 2005;352: Oviedo JA, Schroy PC 3rd. Does celecoxib use increase the risk of cardiovascular events? Gastroenterology 2005;129: Bhattacharyya T, Smith RM. Cardiovascular risks of coxibs: the orthopaedic perspective. J Bone Joint Surg [Am] 2005;87-A: Simon AM, Manigrasso MB, O Connor JP. Cyclo-oxygenase 2 function is essential for bone fracture healing. J Bone Miner Res 2002;17: Zhang X, Schwarz EM, Young DA, et al. Cyclooxygenase-2 regulates mesenchymal cell differentiation into the obsteoblast lineage and is critically involved in bone repair. J Clin Invest 2002;109: Goodman S, Ma T, Trindade M, et al. COX-2 selective NSAID decreases bone ingrowth in vivo. J Orthop Res 2002;20: Van Hecken A, Schwartz JI, Depre M, et al. Comparative inhibitory activity of rofecoxib, meloxicam, diclofenac, ibuprofen, and naproxen on COX-2 versus COX-1 in healthy volunteers. J Clin Pharmacol 2000;40: McMahon JS, Waddell JP, Morton J. Effect of short-course indomethacin on heterotopic bone formation after uncemented total hip arthroplasty. J Arthroplasty 1991;6: Ritter MA, Vaughan RB. Ectopic ossification after total hip arthroplasty: predisposing factors, frequency, and effect on results. J Bone Joint Surg [Am] 1977;59-A: VOL. 89-B, No. 2, FEBRUARY 2007
Gastrointestinal Safety of Coxibs and Outcomes Studies: What s the Verdict?
Vol. 23 No. 4S April 2002 Journal of Pain and Symptom Management S5 Proceedings from the Symposium The Evolution of Anti-Inflammatory Treatments in Arthritis: Current and Future Perspectives Gastrointestinal
More informationAnkylosis due to heterotopic ossification following primary total knee arthroplasty
Acta Orthop. Belg., 2006, 72, 502-506 CASE REPORT Ankylosis due to heterotopic ossification following primary total knee arthroplasty Emmanuel THIENPONT, Thomas SCHMALZRIED, Johan BELLEMANS From the University
More informationThis document has not been circulated to either the industry or Consultants within the Suffolk system.
New Medicine Report Document Status COX II Inhibitors In Acute Analgesia For Suffolk Drug & Therapeutics Committee Date of Last Revision 15 th February 2002 Reviewer s Comments There seems to be a growing
More informationNSAIDs: Side Effects and Guidelines
NSAIDs: Side Effects and James J Hale FY1 Department of Anaesthetics Introduction The non-steroidal anti-inflammatory drugs (NSAIDs) are a diverse group of drugs that have analgesic, antipyretic and anti-inflammatory
More informationBritish Medical Journal. June 3, 2006;332: Patricia M Kearney, Colin Baigent, Jon Godwin, Heather Halls, Jonathan R Emberson, Carlo Patrono
Do selective cyclo-oxygenase-2 inhibitors and traditional non-steroidal anti-inflammatory drugs increase the risk of atherothrombosis? Metaanalysis of randomised trials 1 British Medical Journal June 3,
More informationDario Regis, Andrea Sandri, and Elena Sambugaro. 1. Introduction
BioMed Research International Volume 2013, Article ID 293528, 4 pages http://dx.doi.org/10.1155/2013/293528 Clinical Study Incidence of Heterotopic Ossification after Surface and Conventional Total Hip
More informationCARDIOVASCULAR RISK and NSAIDs
CARDIOVASCULAR RISK and NSAIDs Dr. Syed Ghulam Mogni Mowla Assistant Professor of Medicine Shaheed Suhrawardy Medical College, Dhaka INTRODUCTION NSAIDs are most commonly prescribed drugs Recent evidence
More informationTitle: Non-Steroidal Anti-Inflammatory Drugs for Analgesia in Patients with Fracture: Evidence for Use
Title: Non-Steroidal Anti-Inflammatory Drugs for Analgesia in Patients with Fracture: Evidence for Use Date: 03 June 2008 Context and policy issues: In 2000-2001, 3.4 million Canadians aged 12 years or
More informationTreatment Of Heterotopic Ossification After Hip Arthroscopy
Treatment Of Heterotopic Ossification After Hip Arthroscopy ISHA Annual Scientific Meeting 2012 Boston, MA Crispin Ong MD, Michael Hall MD, Thomas Youm MD Disclosures Consultancy: Arthrex, Depuy Lectures/speakers
More informationRimoxen. Rimoxen! "The Gastro and Cardio friendly anti-inflammatory ingredient"
Rimoxen A Botanical Anti-Inflammatory COX-2 Selective Ingredient Question: How doses Rimoxen compare to the prescription COX-2 inhibitors (Vioxx and Celebrex) and the OTC NSAID pain relievers such as aspirin
More informationRole of radiotherapy in heterotopic ossification: a case report and literature review
Case Report Page 1 of 6 Role of radiotherapy in heterotopic ossification: a case report and literature review Ming-Shan Huang 1, Yu-Hsuan Chen 1,2, Sung-Hsin Kuo 1,2,3,4 1 Division of Radiation Oncology,
More informationNSAIDs and tissue healing - bone. Sigbjørn Dimmen and Lars Engebretsen, Orthopaedic Center, Ullevaal University Hospital, Oslo, Norway
NSAIDs and tissue healing - bone. Sigbjørn Dimmen and Lars Engebretsen, Orthopaedic Center, Ullevaal University Hospital, Oslo, Norway Prevalence of use of NSAIDs in sport Most used drug class in Olympic
More informationHeterotopic ossification (HO) is a common complication
S36 Incidence of Heterotopic Ossification and Effects of Various Prophylactic Methods After Hip Resurfacing Michel J. Le Duff, M.A., Kohtaroh B. Takamura, B.S., and Harlan C. Amstutz, M.D. Michel J. Le
More informationBalanced Analgesia With NSAIDS and Coxibs. Raymond S. Sinatra MD, Ph.D
Balanced Analgesia With NSAIDS and Coxibs Raymond S. Sinatra MD, Ph.D Prostaglandins and Pain The primary noxious mediator released from damaged tissue is prostaglandin (PG) PG is responsible for nociceptor
More informationOne- or two-stage bilateral total hip arthroplasty
Hip One- or two-stage bilateral total hip arthroplasty A PROSPECTIVE, RANDOMISED, CONTROLLED STUDY IN AN ASIAN POPULATION S. Bhan, A. Pankaj, R. Malhotra From the All India Institute of Medical Sciences,
More informationart h ro plasty Heterotopic ossification after total knee 54/61 5 cases after 1-6 years follow-up
46 Acra Orthop Scand 1997; 68 (1): 46-50 Heterotopic ossification after total knee art h ro plasty 54/61 5 cases after 1-6 years follow-up Christof P Rader, Thomas Barthel, Matthias Haase, Matthias Scheidler
More informationCharacteristics of selective and non-selective NSAID use in Scotland
Characteristics of selective and non-selective NSAID use in Scotland Alford KMG 1, Simpson C 1, Williams D 2 1 Department of General Practice & Primary Care, The University of Aberdeen. 2 Department of
More informationReview Article. Safety Profile of Nonsteroidal Antiflammatory Drugs (NSAID) Safety Profile of NSAID
Safety Profile of Nonsteroidal Antiflammatory Drugs (NSAID) R. Stoilov: University Hospital St Ivan Rilski, Clinic of Rheumatology Contact: Rumen Stoilov, Clinic of Rheumatology, University Hospital St
More informationCelecoxib: the need to know for safe prescribing
medicine indications pain management rheumatology Celecoxib: the need to know for safe prescribing Celecoxib is a selective cyclo-oxygenase-2 (COX-2) inhibitor that has been fully subsidised without restriction,
More informationHeterotopic Ossification
Comprehensive Summaries of Uppsala Dissertations from the Faculty of Medicine 1316 Heterotopic Ossification Clinical and Experimental Studies on Risk Factors, Etiology and Inhibition by Non-steroidal Anti-inflammatory
More informationPRESCRIBING SUPPORT TEAM AUDIT: Etoricoxib hypertension safety evaluation
PRESCRIBING SUPPORT TEAM AUDIT: Etoricoxib hypertension safety evaluation DATE OF AUTHORISATION: AUTHORISING GP: PRESCRIBING SUPPORT TECHNICIAN: SUMMARY This audit has been designed to ensure that patients
More informationHave COX-2 inhibitors influenced the co-prescription of anti-ulcer drugs with NSAIDs?
et al. DOI:10.1111/j.1365-2125.2003.02012.x British Journal of Clinical Pharmacology Have COX-2 inhibitors influenced the co-prescription of anti-ulcer drugs with NSAIDs? Mary Teeling, Kathleen Bennett
More informationDisclosure. Learning Objectives 1/17/2018. Pumping the Breaks in Pain Management: An Update on Cardiovascular Risk with NSAID Use
Disclosure Pumping the Breaks in Pain Management: An Update on Cardiovascular Risk with Liz Van Dril, PharmD, BCPS PGY2 Ambulatory Care Resident January 17 th, 2018 Dr. Liz Van Dril has no actual or potential
More informationNSAID Use in Post- Myocardial Infarction Patients. Leah Jackson, BScPhm Pharmacy Resident Cardiology Rotation February 28, 2007
NSAID Use in Post- Myocardial Infarction Patients Leah Jackson, BScPhm Pharmacy Resident Cardiology Rotation February 28, 2007 Objectives By the end of the presentation, the audience will be able to use
More informationNSAID Use in Post- Myocardial Infarction Patients
NSAID Use in Post- Myocardial Infarction Patients Leah Jackson, BScPhm Pharmacy Resident Cardiology Rotation February 28, 2007 Objectives By the end of the presentation, the audience will be able to use
More informationShared Care Protocol for the Prescription and Supply of Low Molecular Weight Heparins
Tameside Hospital NHS Foundation Trust and NHS Tameside and Glossop Shared Care Protocol for the Prescription and Supply of Low Molecular Weight Heparins Version 5.2 Version: 5.2 Authorised by: Joint Medicines
More informationDrug Class Review on Cyclo-oxygenase (COX)-2 Inhibitors and Non-steroidal Anti-inflammatory Drugs (NSAIDs)
Drug Class Review on Cyclo-oxygenase (COX)-2 Inhibitors and Non-steroidal Anti-inflammatory Drugs (NSAIDs) Final Report Update 3 Evidence Tables November 2006 Original Report Date: May 2002 Update 1 Report
More informationModelling therapeutic strategies in the treatment of osteoarthritis: an economic evaluation of meloxicam versus diclofenac and piroxicam Tavakoli M
Modelling therapeutic strategies in the treatment of osteoarthritis: an economic evaluation of meloxicam versus diclofenac and piroxicam Tavakoli M Record Status This is a critical abstract of an economic
More informationSELECTED ABSTRACTS. Figure. Risk Stratification Matrix A CLINICIAN S GUIDE TO THE SELECTION OF NSAID THERAPY
SELECTED ABSTRACTS A CLINICIAN S GUIDE TO THE SELECTION OF NSAID THERAPY The authors of this article present a 4-quadrant matrix based on 2 key clinical parameters: risk for adverse gastrointestinal (GI)
More informationSupplementary appendix
Supplementary appendix This appendix formed part of the original submission and has been peer reviewed. We post it as supplied by the authors. Supplement to: Coxib and traditional NSAID Trialists (CNT)
More informationEarly failure of total hip replacements implanted at distant hospitals to reduce waiting lists
: 31 35 doi 10.1308/1478708051450 Audit Early failure of total hip replacements implanted at distant hospitals to reduce waiting lists Jac Ciampolini, Matthew JW Hubble Princess Elizabeth Orthopaedic Centre,
More informationCarlo Biz 1*, Davide Pavan 1, Antonio Frizziero 2, Ala Baban 2 and Claudio Iacobellis 1
Biz et al. Journal of Orthopaedic Surgery and Research (2015) 10:176 DOI 10.1186/s13018-015-0317-2 RESEARCH ARTICLE Open Access Heterotopic ossification following hip arthroplasty: a comparative radiographic
More informationScottish Medicines Consortium
Scottish Medicines Consortium ketoprofen/, 100mg/20mg; 200mg/20mg modified release capsules (Axorid ) No. (606/10) Meda Pharmaceuticals 05 February 2010 The Scottish Medicines Consortium (SMC) has completed
More informationF.L.P SABOU 1 R. D. NECULA 1, 2 A.M. PASCU 2 I. ŞAMOTĂ 2
Bulletin of the Transilvania University of Braşov Series VI: Medical Sciences Vol. 8 (57) No. 2-2015 THE INFLUENCE OF PROSTHESIS TYPE AND SURGICAL APPROACH IN THE DEVELOPMENT OF HETEROTOPIC OSSIFICATIONS
More informationNONSTEROIDAL ANTI- INFLAMMATORY DRUGS
NONSTEROIDAL ANTI- INFLAMMATORY DRUGS MRS. M.M. HAS A 3 YR. HX OF PROGRESSIVE RIGHT HIP PAIN. THE PAIN INCREASES WITH WEIGHT BEARING ACTIVITY. PT. HAS BEEN ON ACETAMINOPHEN WITHOUT RELIEF. PERTINENT LABS
More informationSHIELDING OF THE HIP PROSTHESIS DURING RADIATION THERAPY FOR HETEROTOPIC OSSIFICATION IS ASSOCIATED WITH INCREASED FAILURE OF PROPHYLAXIS
doi:10.1016/j.ijrobp.2006.11.007 Int. J. Radiation Oncology Biol. Phys., Vol. 67, No. 5, pp. 1499 1505, 2007 Copyright 2007 Elsevier Inc. Printed in the USA. All rights reserved 0360-3016/07/$ see front
More informationNSAIDs Overview. Souraya Domiati, Pharm D, MS
NSAIDs Overview Souraya Domiati, Pharm D, MS Case A 32 years old shows up into your pharmacy asking for an NSAID for his ankle pain He smokes1 pack/day His BP is 125/75mmHg His BMI is 35kg/m2 His is on
More informationCOX-2 inhibitors: A cautionary tale. October 2, 2006
COX-2 inhibitors: A cautionary tale October 2, 2006 Molecular interventions in human disease... An approach as old as human civilization. With whom the herbs have come together Like kingly chiefs unto
More informationDatabase of Abstracts of Reviews of Effects (DARE) Produced by the Centre for Reviews and Dissemination Copyright 2017 University of York.
A comparison of the cost-effectiveness of five strategies for the prevention of non-steroidal anti-inflammatory drug-induced gastrointestinal toxicity: a systematic review with economic modelling Brown
More informationTITLE: Acetylsalicylic Acid for Venous Thromboembolism Prophylaxis: A Review of Clinical Evidence, Benefits and Harms
TITLE: Acetylsalicylic Acid for Venous Thromboembolism Prophylaxis: A Review of Clinical Evidence, Benefits and Harms DATE: 23 August 2011 CONTEXT AND POLICY ISSUES: Thromboembolism occurs when a blood
More informationTotal Hip Arthroplasty Performed Using Conventional and Computer-Assisted, Tissue- Preserving Techniques 6
Total Hip Arthroplasty Performed Using Conventional and Computer-Assisted, Tissue- Preserving Techniques 6 Stephen B. Murphy, MD, Timo M. Ecker, MD and Moritz Tannast, MD Introduction Less invasive techniques
More informationClinical and radiological results of the stemmed Mc Minn cup in hip revision surgery
Acta Orthop. Belg., 2010, 76, 58-62 ORIGINAL STUDY Clinical and radiological results of the stemmed Mc Minn cup in hip revision surgery Pax WILLEMSE, Rene M. CASTELEIN, Paul L. P. A. BOM, Aart VERBURG,
More informationPain therapeutics. Acetaminophen/NSAIDs Acute pain Osteoarthritis Migraine Acute Gout Neuropathic pain
Pain therapeutics Acetaminophen/NSAIDs Acute pain Osteoarthritis Migraine Acute Gout Neuropathic pain James McCormack, Pharm.D. Professor Faculty of Pharmaceutical Sciences, UBC Common types of pain killers
More informationNON STEROIDEAL ANTI-INFLAMMATORY DRUGS AND CARDIOVASCULAR RISK. Advances in Cardiac Arrhythmias and Great Innovations in Cardiology
NON STEROIDEAL ANTI-INFLAMMATORY DRUGS AND CARDIOVASCULAR RISK Advances in Cardiac Arrhythmias and Great Innovations in Cardiology Torino, October 15, 2016 Giuseppe Di Pasquale Direttore Dipartimento Medico
More informationNSAID Regional Audit Group Presentation. Audit Group: Dr Richard Latten, Ruth Clark, Dr Sarah Fradsham, Dr Seamus Coyle, Claire Johnston
NSAID Regional Audit Group Presentation Audit Group: Dr Richard Latten, Ruth Clark, Dr Sarah Fradsham, Dr Seamus Coyle, Claire Johnston Thank you from the audit group for all who participated in the data
More informationCOX-2 inhibitors: A cautionary tale
COX-2 inhibitors: A cautionary tale October 1, 2007 Molecular interventions in human disease... An approach as old as human civilization. With whom the herbs have come together Like kingly chiefs unto
More information(i) Is there a registered protocol for this IPD meta-analysis? Please clarify.
Reviewer: 4 Additional Questions: Please enter your name: Stefanos Bonovas Job Title: Researcher Institution: Humanitas Clinical and Research Institute, Milan, Italy Comments: The authors report the results
More informationDoes the use of NSAIDs amongst patients with long-bone fractures increase the risk of non-union: A structured review protocol for a systematic review.
1. TITLE OF PROJECT Does the use of NSAIDs amongst patients with long-bone fractures increase the risk of non-union: A structured review protocol for a systematic review. 2. TEAM and LEAD Alder Hey Orthopaedic
More informationThink Before or Sink After: Choosing an Appropriate NSAID by Balancing Gastrointestinal and Cardiovascular Risks
NEWS AND PERSPECTIVES Think Before or Sink After: Choosing an Appropriate NSAID by Balancing Gastrointestinal and Cardiovascular Risks Jyh-Ming Liou, 1,2 Ming-Shiang Wu, 1 * Jaw-Town Lin 1,3 Nonsteroidal
More informationIbuprofen versus other non-steroidal anti-in ammatory drugs: use in general practice and patient perception
Aliment Pharmacol Ther 2000; 14: 187±191. Ibuprofen versus other non-steroidal anti-in ammatory drugs: use in general practice and patient perception C. J. HAWKEY 1,D.J.E.CULLEN 1,9,G.PEARSON 1,S.HOLMES
More informationResults of Conversion Total Hip Prosthesis Performed Following Painful Hemiarthroplasty
M Nomura, S The Journal et al. of International Medical Research Endovascular 2000; 28: Embolization 307 312 of Unruptured Results of Conversion Total Hip Prosthesis Performed Following Painful Hemiarthroplasty
More informationOSTEOARTHRITIS; EFFICACY AND SAFETY OF ACECLOFENAC IN THE TREATMENT: A RANDOMIZED DOUBLE-BLIND COMPARATIVE CLINICAL TRIAL VERSUS DICLOFENAC
The Professional Medical Journal www.theprofesional.com ORIGINAL PROF-416 OSTEOARTHRITIS; EFFICACY AND SAFETY OF ACECLOFENAC IN THE TREATMENT: A RANDOMIZED DOUBLE-BLIND COMPARATIVE CLINICAL TRIAL VERSUS
More informationAnti-inflammatory drugs
Anti-inflammatory drugs 1 Inflammatory process 1. stimulus (cut) 2. Initial local vasoconstriction( blood loss) 3. vasodilation, local immune/inflammatory reaction (heat, redness) 4. swelling and pain
More informationThe first stop for professional medicines advice. Community Pharmacy NSAID Gastro-Intestinal Safety Audit
Community Pharmacy NSAID Gastro-Intestinal Safety Audit Working with Primary Care Commissioning, Strategy and Innovation Directorate The first stop for professional medicines advice www.sps.nhs.uk Community
More informationPerioperative VTE Prophylaxis
Perioperative VTE Prophylaxis Gregory J. Misky, M.D. Assistant Professor of Medicine University Of Colorado Denver You recommend the following 72 y.o. man admitted for an elective R hip repair. Patient
More informationDevelopmental Dysplasia of the Hip Good Results of Later Total Hip Arthroplasty
The Journal of Arthroplasty Vol. 23 No. 2 2008 Developmental Dysplasia of the Hip Good Results of Later Total Hip Arthroplasty 7135 Primary Total Hip Arthroplasties after Developmental Dysplasia of the
More informationComparison of the efficacy and tolerance of isoxicam and piroxicam following surgery for skiing accidents
Br. J. clin. Pharmac. (1986), 22, 161S-165S Comparison of the efficacy and tolerance of isoxicam and piroxicam following surgery for skiing accidents P. MASSART & 'H. BEZES Clinique Chirurgicale et Traumatologique
More informationAbwägung zwischen Schaden und Nutzen medizinischer Interventionen
Abwägung zwischen Schaden und Nutzen medizinischer Interventionen Peter Jüni Institut für Sozial and Präventivmedizin, Universität Bern CTU Bern, Inselspital Bern Outline Wall Street, New York, Sept 30,
More informationHeterotopic ossification is an
CE Heterotopic Ossification Laurie Adams, EdD, R.T.(T) Heterotopic ossification is a complicated and significant medical problem characterized by abnormal growth of bone in soft tissues. It occurs most
More informationClinical Practice Guideline for Patients Requiring Total Hip Replacement
Clinical Practice Guideline for Patients Requiring Total Hip Replacement Inclusions Patients undergoing elective total hip replacement Exclusions Patients with active local or systemic infection or medical
More informationLOW DOSE ASPIRIN CARDIOVASCULAR DISEASE FOR PROPHYLAXIS OF FOR BACKGROUND USE ONLY NOT TO BE USED IN DETAILING
LOW DOSE ASPIRIN FOR PROPHYLAXIS OF CARDIOVASCULAR DISEASE FOR BACKGROUND USE ONLY NOT TO BE USED IN DETAILING Use of Low Dose Aspirin to Treat and Prevent Cardiovascular Disease In recent decades, aspirin
More informationAssessment of Prognosis of Patients with Intertrochanteric Fractures Undergoing Treatment with PFN: An Observational Study
Original article: Assessment of Prognosis of Patients with Intertrochanteric Fractures Undergoing Treatment with PFN: An Observational Study Gajraj Singh 1, Sandhya Gautam 2 1Assistant Professor, Department
More informationAN AUDIT: THROMBOPROPHYLAXIS FOR TOTAL HIP REPLACEMENT PATIENTS AT NORTHWICK PARK AND CENTRAL MIDDLESEX HOSPITALS
The West London Medical Journal 2010 Vol 2 No 4 pp 19-24 AN AUDIT: THROMBOPROPHYLAXIS FOR TOTAL HIP REPLACEMENT PATIENTS AT NORTHWICK PARK AND CENTRAL MIDDLESEX HOSPITALS Soneji ND Agni NR Acharya MN Anjari
More informationAccounting for cardiovascular risk when prescribing NSAIDs
MEDICINES OPTIMISATION Accounting for cardiovascular risk when prescribing NSAIDs DAVID LAIGHT It is now recognised that oral NSAIDs can increase the risk of cardiovascular events, including myocardial
More informationIroko Pharmaceuticals Receives FDA Approval for VIVLODEX - First Low Dose SoluMatrix Meloxicam for Osteoarthritis Pain
Iroko Pharmaceuticals Receives FDA Approval for VIVLODEX - First Low Dose SoluMatrix Meloxicam for Osteoarthritis Pain VIVLODEX Developed to Align with FDA NSAID Recommendations Proven Efficacy at Low
More informationAlgorithm for Use of Non-steroidal Anti-inflammatories (NSAIDs)
Algorithm for Use of Non-steroidal Anti-inflammatories (NSAIDs) Page 3 Publisher Conseil du médicament www.cdm.gouv.qc.ca Coordination Anne Fortin, Pharmacist Development Conseil du médicament Fédération
More informationClinical Investigations and Reports. Cardiovascular Thrombotic Events in Controlled, Clinical Trials of Rofecoxib
Clinical Investigations and Reports Cardiovascular Thrombotic Events in Controlled, Clinical Trials of Rofecoxib Marvin A. Konstam, MD; Matthew R. Weir, MD; Alise Reicin, MD; Deborah Shapiro, DrPh; Rhoda
More informationNon-steroidal anti-inflammatory drugs and gastrointestinal damage problems and solutions
82 University of Glasgow and Department of Gastroenterology, Royal Infirmary, Glasgow Correspondence to: Professor R I Russell, 28 Ralston Road, Bearsden, Glasgow G61 3BA rirla@aol.com Submitted 26 October
More informationTIVORBEX Now Available in U.S. Pharmacies for the Treatment of Acute Pain
TIVORBEX Now Available in U.S. Pharmacies for the Treatment of Acute Pain Second Low-Dose SoluMatrix NSAID from Iroko Now Available by Prescription PHILADELPHIA, June 29, 2015 Iroko Pharmaceuticals, LLC,
More informationBone Bangalore
Dr Suresh Annamalai MBBS, MRCS(Edn), FRCS( Tr & Orth)(Edn), FEBOT(European Board), Young Hip and Knee Fellowship(Harrogate, UK) HOD & Consultant Arthroplasty and Arthroscopic Surgeon Manipal Hospital,
More informationLow revision rate after total hip arthroplasty in patients with pediatric hip diseases
6 Acta Orthopaedica 2012; 83 (5): x x 1 Low revision rate after total hip arthroplasty in patients with pediatric hip diseases Evaluation of 14,403 THAs due to DDH, SCFE, or Perthes disease and 288,435
More informationSafety of Arthrocentesis and Joint Injection in Patients Receiving Anticoagulation at Therapeutic Levels
CLINICAL RESEARCH STUDY Safety of Arthrocentesis and Joint Injection in Patients Receiving Anticoagulation at Therapeutic Levels Imdad Ahmed, MBBS, a,b Elie Gertner, MD a,b a Department of Internal Medicine,
More informationOutcome of Girdlestone s resection arthroplasty following complications of proximal femoral fractures
Acta Orthop. Belg., 2006, 72, 555-559 ORIGINAL STUDY Outcome of Girdlestone s resection arthroplasty following complications of proximal femoral fractures Himanshu SHARMA, Rahul KAKAR From the Royal Alexandra
More informationPapers. Abstract. Introduction. Methods. Jonathan J Deeks, Lesley A Smith, Matthew D Bradley
Efficacy, tolerability, and upper gastrointestinal safety of celecoxib for treatment of osteoarthritis and rheumatoid arthritis: systematic review of randomised controlled trials Jonathan J Deeks, Lesley
More informationASPIRIN AND VASCULAR DISEASE
ASPIRIN AND VASCULAR DISEASE SUMMARY Aspirin is an effective antiplatelet agent for patients with cardiovascular and cerebrovascular disease. Incidence of adverse effects and drug interactions increases
More informationCirculation. 2001;104: ; originally published online October 15, 2001; doi: /hc
Cardiovascular Thrombotic Events in Controlled, Clinical Trials of Rofecoxib Marvin A. Konstam, Matthew R. Weir, Alise Reicin, Deborah Shapiro, Rhoda S. Sperling, Eliav Barr and Barry J. Gertz Circulation.
More informationStatement from the Steering Committee of the Alzheimer s Disease Anti inflammatory Prevention Trial (ADAPT)
Statement for FDA Joint Advisory Committee page 1 Statement from the Steering Committee of the Alzheimer s Disease Anti inflammatory Prevention Trial (ADAPT) for communication to the FDA Arthritis Advisory
More informationSPECIAL REPORT. Aspirin and Risk of Gastroduodenal Complications
CLINICAL GASTROENTEROLOGY AND HEPATOLOGY 2009;7:725 735 SPECIAL REPORT Proton Pump Inhibitors for Gastroduodenal Damage Related to Nonsteroidal Anti-inflammatory Drugs or Aspirin: Twelve Important Questions
More informationA comparison of Ketoprofen and Diclofenac for acute musculoskeletal pain relief: a prospective randomised clinical trial
Hong Kong Journal of Emergency Medicine A comparison of Ketoprofen and Diclofenac for acute musculoskeletal pain relief: a prospective randomised clinical trial P Ng, CW Kam, HH Yau Objectives: To compare
More informationEffect of surgical approach on the early outcome of total hip replacement for femoral neck fractures
Acta Orthop. Belg., 23, 79, 667-67 ORIGINAL STUDY Effect of surgical approach on the early outcome of total hip replacement for femoral neck fractures Ahmed M. Mohamed, Daoud Makki, James Gibbs From the
More informationPostoperative pain management: Analgesics, algorithms and patient activation
Postoperative pain management: Analgesics, algorithms and patient activation Alfred Deakin Prof. Mari Botti Deakin University/Epworth HealthCare Victorian Perioperative Nurses Group 60 th State Conference,
More informationPronaxen 250 mg tablet OTC , Version 1.3 PUBLIC SUMMARY OF THE RISK MANAGEMENT PLAN
Pronaxen 250 mg tablet OTC 25.9.2015, Version 1.3 PUBLIC SUMMARY OF THE RISK MANAGEMENT PLAN VI.2 Elements for a Public Summary VI.2.1 Overview of disease epidemiology Pronaxen 250 mg is indicated for
More informationCardiovascular Risk of Celecoxib in 6 Randomized Placebo-controlled Trials: The Cross Trial Safety Analysis
Cardiovascular Risk of Celecoxib in 6 Randomized Placebo-controlled Trials: The Cross Trial Safety Analysis Scott D. Solomon, MD, Janet Wittes, PhD, Ernest Hawk, MD, MPH for the Celecoxib Cross Trials
More informationPain: A Public Health Challenge. NSAIDS for Managing Pain. Iroko: Innovators in Analgesia
Pain: A Public Health Challenge Despite advances in understanding and treatment, pain remains a major public health challenge 1 that exacts a significant personal and economic toll on Americans 2. Pain
More informationEICOSANOID METABOLISM
1 EICOSANOID METABOLISM EICOSANOIDS C20 polyunsaturated fatty acids e.g. Arachidonic acid Eicosanoids physiologically, pathologically and pharmacologically active compounds PG Prostaglandins TX - Thromboxanes
More informationMUSCULOSKELETAL PHARMACOLOGY. A story of the inflamed
MUSCULOSKELETAL PHARMACOLOGY A story of the inflamed 1 INFLAMMATION Pathophysiology Inflammation Reaction to tissue injury Caused by release of chemical mediators Leads to a vascular response Fluid and
More informationIroko Pharmaceuticals Announces Acceptance for Filing of ZORVOLEX snda for the Treatment of Osteoarthritis Pain in Adults
Iroko Pharmaceuticals Announces Acceptance for Filing of ZORVOLEX snda for the Treatment of Osteoarthritis Pain in Adults First Lower Dose NSAID Using SoluMatrix Fine Particle Technology to be Reviewed
More informationVenothromboembolism prophylaxis: Trauma and Orthopaedics Clinical guideline, V2
Clinical Guideline Venothromboembolism prophylaxis: Trauma and Orthopaedics 11/11/11 TEMPORARY GUIDANCE There is no prophylactic tinzaparin available in the Trust currently. Please substitute enoxaparin
More informationKlinische und radiologische Ergebnisse einer «isoelastischen» Pfanne
Klinische und radiologische Ergebnisse einer «isoelastischen» Pfanne Martin Beck, Prof. Dr.med. Klinik für Orthopädie und Unfallchirurgie Luzerner Kantonsspital resorption of acetabular bone can be observed
More informationAspirin as Venous Thromboprophylaxis
Canadian Society of Internal Medicine Nov 2, 2017 Aspirin as Venous Thromboprophylaxis Bill Geerts, MD, FRCPC Thromboembolism Consultant, Sunnybrook HSC Professor of Medicine, University of Toronto Disclosures
More informationAGGRESSIVE GRANULOMATOUS LESIONS AFTER HIP ARTHROPLASTY
AGGRESSIVE GRANULOMATOUS LESIONS AFTER HIP ARTHROPLASTY KAJ TALLROTH, ANTTI ESKOLA, SEPPO SANTAVIRTA, YRJ T. KONTTINEN, T. SAM LINDHOLM From the Orthopaedic Hospitalofthe Invalid Foundation, Helsinki We
More informationMonth/Year of Review: January 2012 Date of Last Review: February 2007
Drug Use Research & Management Program Oregon State University, 500 Summer Street NE, E35, Salem, Oregon 97301-1079 Phone 503-945-5220 Fax 503-947-1119 Month/Year of Review: January 2012 Date of Last Review:
More informationCementless Oxford unicompartmental knee replacement shows reduced radiolucency at one year
Cementless Oxford unicompartmental knee replacement shows reduced radiolucency at one year H. Pandit, C. Jenkins, D. J. Beard, J. Gallagher, A. J. Price, C. A. F. Dodd, J. W. Goodfellow, D. W. Murray From
More informationReview Article. NSAID Gastropathy: An Update on Prevention. Introduction. Risk Factors. Kam-Chuen Lai
Review Article NSAID Gastropathy: An Update on Prevention Kam-Chuen Lai Abstract: Keywords: Adverse reactions to non-steroidal anti-inflammatory drugs (NSAIDs) are common. Upper gastrointestinal complications
More informationClinical Practice Guidelines: Can I Learn to Live With Them? What s in the News These Days 2/11/2016. Excessive Costs of Medical Care
Orthopaedic Trauma Fracture Care: Pushing the Envelope San Diego Clinical Practice Guidelines: Can I Learn to Live With Them? Andrew H. Schmidt, MD What s in the News These Days Excessive Costs of Medical
More informationAN NSAID WITH A BALANCED COX-1 & COX-2 INHIBITORY EFFECT
AN NSAID WITH A BALANCED COX-1 & COX-2 INHIBITORY EFFECT A balanced cox-1 and cox-2 inhibitor Metabolisim and Bioavailabillty of Lornoxicam (3) Relative selectivity of agents as inhibitors of cox-1 and
More informationPrevention of Deep-Vein Thrombosis After Total Knee Arthroplasty in Asian Patients COMPARISON OF LOW-MOLECULAR-WEIGHT HEPARIN AND INDOMETHACIN
136 COPYRIGHT 2004 BY THE JOURNAL OF BONE AND JOINT SURGERY, INCORPORATED Prevention of Deep-Vein Thrombosis After Total Knee Arthroplasty in Asian Patients COMPARISON OF LOW-MOLECULAR-WEIGHT HEPARIN AND
More informationCover Page. The handle holds various files of this Leiden University dissertation.
Cover Page The handle http://hdl.handle.net/1887/38039 holds various files of this Leiden University dissertation. Author: Embden, Daphne van Title: Facts and fiction in hip fracture treatment Issue Date:
More informationHaukeland University Hospital, Bergen
This article was downloaded by:[universitetsbiblioteket i Bergen] On: 2 November 2007 Access Details: [subscription number 768372013] Publisher: Informa Healthcare Informa Ltd Registered in England and
More information